Article Versions Notes

Del Casale A, Simmaco M, Modesti MN, Zocchi C, Arena JF, Bilotta I, Alcibiade A, Sarli G, Cutillo L, Antonelli G, et al. DRD2, DRD3, and HTR2A Single-Nucleotide Polymorphisms Involvement in High Treatment Resistance to Atypical Antipsychotic Drugs. Biomedicines. 2023; 11(7):2088. https://doi.org/10.3390/biomedicines11072088

Del Casale, Antonio, Maurizio Simmaco, Martina Nicole Modesti, Clarissa Zocchi, Jan Francesco Arena, Irene Bilotta, Alessandro Alcibiade, Giuseppe Sarli, Lorenzo Cutillo, Giulia Antonelli, and et al. 2023. "DRD2, DRD3, and HTR2A Single-Nucleotide Polymorphisms Involvement in High Treatment Resistance to Atypical Antipsychotic Drugs" Biomedicines 11, no. 7: 2088. https://doi.org/10.3390/biomedicines11072088

Del Casale, A., Simmaco, M., Modesti, M. N., Zocchi, C., Arena, J. F., Bilotta, I., Alcibiade, A., Sarli, G., Cutillo, L., Antonelli, G., La Spina, E., De Luca, O., Preissner, R., Borro, M., Gentile, G., Girardi, P., & Pompili, M. (2023). DRD2, DRD3, and HTR2A Single-Nucleotide Polymorphisms Involvement in High Treatment Resistance to Atypical Antipsychotic Drugs. Biomedicines, 11(7), 2088. https://doi.org/10.3390/biomedicines11072088